In this regard, the BYLieve (NCT03056755) study is being conducted to evaluate the effect of alpelisib in the subset of HR+/HER2− recurrent BC patients with PIK3CA mutations who have progressed on prior CDK4/6 inhibitor treatment. Here, CDK4 is linked to breast cancer.